Tag Archives: Johnson & Johnson

Johnson & Johnson Announces Launch of Africa Innovation Challenge to Support Continent’s Entrepreneurs and Develop Local Consumer Health Solutions

Challenge Reflects Company’s Comprehensive Approach to Advancing Health and Innovation on the Continent

CAPE TOWN, South Africa, Nov. 1, 2016 /PRNewswire/ — As part of its longstanding commitment to Africa, Johnson & Johnson (NYSE: JNJ) today announced the launch of the Africa Innovation Challenge, an initiative to support Africa’s vibrant and growing innovation ecosystem and to help develop important and locally sustainable consumer health solutions.  The challenge is the latest initiative in the company’s comprehensive approach to advancing health and innovation worldwide. The Johnson & Johnson Family of Companies’ presence in Africa dates back more than 80 years and includes business operations, public health programs and corporate citizenship.

Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/7967451-jnj-africa-innovation-challenge

“Through the Africa Innovation Challenge, we have the opportunity to support the continent’s top entrepreneurs through mentorship and other resources, and by working together with local talent, to bring forward new solutions to local health care challenges,” said Paul Stoffels, M.D., Executive Vice President and Chief Scientific Officer, Johnson & Johnson.

Earlier this year, Johnson & Johnson announced its global public health (GPH) strategy in Cape Town, South Africa, where its companies also opened their GPH operations headquarters. The operations expand upon the company’s legacy and presence in Africa, which began in 1936, and brings additional investments to the more than 1,500 employees and three manufacturing sites within the Johnson & Johnson Family of Companies already present on the continent.

“Our goal is to improve the health and well-being of families and communities around the world,” said Josh Ghaim, Ph.D., Chief Technology Officer, Johnson & Johnson Consumer Inc. “With its focus on consumer health care, the Africa Innovation Challenge will help to surface important issues impacting local communities. We look forward to engaging with the continent’s top entrepreneurs and scientists, and through collaboration, helping advance their ideas and bringing meaningful solutions across three very important health care areas.”

The Africa Innovation Challenge seeks novel ideas that focus on three critical health areas: promoting early child development and maternal health; empowering young women; and improving family well-being. Challenge participant(s) with the best solutions will receive up to US $100,000 in funding and mentorship from scientists, engineers and researchers in the Johnson & Johnson Consumer Research & Development organization.

“The Africa Innovation Challenge is an exciting initiative for our entrepreneurial and scientific communities,” said Thomas Maina Kariuki, Ph.D., Director, Alliance for Accelerating Excellence in Science in Africa, African Academy of Sciences (AAS).  “The challenge provides the kind of mentorship and resources that can really advance an entrepreneur’s vision, and it showcases the terrific young talent across Africa. AAS is proud to support this initiative and we look forward to collaborating throughout the challenge.”

The winner(s) of the challenge could also receive dedicated space at a lab facility in Africa throughout their product or service development, dependent on the needs of the solution submission. Award recipients will be announced in February 2017.

Challenge submissions may originate from anywhere in Africa, and from one or more individuals, teams or companies; subject to certain eligibility requirements set out in the terms and conditions for the challenge. Solutions will be evaluated based on their ability to meet the following criteria:

  • Solution submission addresses at least one of the three challenge categories: Promoting Early Child Development & Maternal Health in Africa; Empowering Young Girls in Africa; Improving Family Well-being in Africa
  • Submission is innovative and creative
  • Submission is scalable
  • Submission outlines a commercialization plan and how the award would help the applicant reach a critical milestone within the timeframe of a single year

To apply to the challenge and review the applicable terms and conditions, please visit the Africa Innovation Challenge website. The deadline to submit applications is January 17, 2017.  Neither Johnson & Johnson nor any of its companies is granted any rights to applicant ideas as a result of their participation in the challenge.  Applicants and winners remain free to continue the further development of their ideas on their own.

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,900 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Logo – http://photos.prnewswire.com/prnh/20160831/403394LOGO

Johnson & Johnson lance un appel aux idées innovantes afin de réduire les infections au VIH en Afrique subsaharienne

Les partenaires DREAMS annoncent un défi de l’innovation de 85 millions $ axé sur les solutions pour les adolescentes et les jeunes femmes

NEW BRUNSWICK, New Jersey, le 18 février 2016 /PRNewswire/ — Aujourd’hui, Johnson & Johnson (NYSE : JNJ) a lancé un appel pour des idées innovantes dans le cadre du défi de l’innovation DREAMS qui est soutenu par le Plan d’urgence du Président des États-Unis pour la lutte contre le SIDA (PEPFAR – U.S. President’s Emergency Plan for AIDS Relief), Janssen Pharmaceutica, NV, l’une des sociétés pharmaceutiques Janssen de Johnson & Johnson, et ViiV Healthcare. Les propositions d’innovations révolutionnaires permettant de réduire les infections au VIH chez les adolescentes et les jeunes femmes dans dix pays subsahariens sont actuellement acceptées. La date limite de soumission pour être récompensé est fixée au 28 mars 2016.

Johnson & Johnson issued a call for innovative ideas to reduce HIV infections in adolescent girls and young women in sub-Saharan Africa as part of the DREAMS Innovation Challenge, sponsored by Janssen Pharmaceutica, NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), and ViiV Healthcare.

Photo – http://photos.prnewswire.com/prnh/20160216/333964

Au total, 85 millions $ seront remis pour récompenser les solutions durables innovantes dans six domaines prioritaires du défi qui donneront aux jeunes femmes la possibilité de vivre la vie déterminée, résiliente, responsabilisée, exempte de SIDA, encadrée et sûre (Determined, Resilient, Empowered, AIDS-Free, Mentored, and Safe, DREAMS soit RÊVES en français) qu’elles méritent. Les solutions gagnantes devront faire preuve d’un état de préparation adéquat pour être rapidement mises en œuvre dans un ou plusieurs des dix pays DREAMS et les effets devront être visibles dans un délai de deux ans, avec des perspectives de changement à long terme.

« Nous croyons que les innovations révolutionnaires nécessaires pour réduire les infections au VIH chez les adolescentes et les jeunes femmes peuvent venir de n’importe où dans le monde », a déclaré Paul Stoffels, M.D., conseiller scientifique en chef et président mondial, pharmaceutique, Johnson & Johnson. « Notre espoir en soutenant le défi de l’innovation DREAMS est de générer de nouvelles idées afin de nous aider à atteindre d’ici la fin de l’année 2017 une baisse de 40 pour cent des infections au VIH chez les adolescentes et les jeunes femmes vivant dans dix pays subsahariens ».

Le SIDA est la principale cause de mortalité chez les femmes en âge de procréer dans les pays à revenu faible ou à revenu intermédiaire. Les adolescentes et jeunes femmes représentent 380 000 nouvelles infections par an, soit plus de 7 000 nouvelles infections par semaine globalement.

« Alors que nous avons réalisé des progrès considérables dans la réponse mondiale au VIH/SIDA, les adolescentes et jeunes femmes ont été largement oubliées », a déclaré l’ambassadrice Deborah L. Birx, coordonnatrice de la lutte mondiale contre le SIDA des États-Unis et représentante spéciale aux États-Unis pour la diplomatie en matière de santé mondiale. « Avec les filles et jeunes femmes comptant pour près de 71 pour cent de l’ensemble des nouvelles infections au VIH parmi les adolescents en Afrique subsaharienne, nous avons un besoin urgent de solutions innovantes qui les responsabilisent afin de préserver leur santé et leur permettre de poursuivre leurs rêves ».

« Une nouvelle réflexion et des approches à fort impact sont nécessaires pour s’attaquer aux nombreuses complexités à l’origine de cette crise mondiale », a déclaré Jaak Peeters, responsable de l’organisation pour la santé publique mondiale de Johnson & Johnson. « En nous attaquant aux facteurs et à la complexité qui affectent ces jeunes femmes à un niveau fondamental, nous espérons améliorer de manière quantifiable la situation sanitaire et créer un changement pérenne. Ce sont des composantes importantes de l’approche de Johnson & Johnson pour améliorer la santé publique mondiale ».

Johnson & Johnson, par le biais de ses sociétés pharmaceutiques Janssen, a rejoint le partenariat DREAMS en tant que partenaire de référence en décembre dernier. Le partenariat ambitieux d’un montant de 385 millions $ apporte un ensemble essentiel d’approches fondées sur des données probantes qui vont au-delà du secteur de la santé et s’attaquent aux facteurs structurels qui augmentent directement ou indirectement les risques pour les jeunes filles de contracter le VIH, et notamment la pauvreté, l’inégalité des sexes, les violences sexuelles et le manque d’éducation. Le partenariat DREAMS inclut également PEPFAR, la fondation Bill & Melinda Gates, Girl Effect, Gilead Sciences, et ViiV Healthcare.

Produire un impact durable dans la santé publique globale

Combattre le VIH est une composante essentielle de la longue tradition de Johnson & Johnson en matière d’engagement et de partenariat pour améliorer la santé publique globale des personnes, familles et communautés du monde entier. Par le biais de son organisation pour la santé publique, la société vise à apporter des solutions fondées sur des données probantes intégrées pour répondre de manière complète aux besoins en matière de santé et produire un impact significatif et pérenne dans trois domaines prioritaires essentiels : le VIH, la santé maternelle et infantile et la tuberculose ultrarésistante (TB-UR) et multirésistante (TB-MR).

Informations concernant les candidatures pour le défi de l’innovation DREAMS

Le partenariat DREAMS prévoit d’annoncer les vainqueurs à la mi-juillet, suivi par la mise en œuvre au début de l’automne 2016. Les prix pour les défis iront de 100 000 $ à 40 millions $. Les solutions recherchées seront mises en œuvre au Kenya, au Lesotho, au Malawi, en Mozambique, en Afrique du Sud, au Swaziland, en Tanzanie, en Ouganda, en Zambie et au Zimbabwe.

Les candidats doivent soumettre une expression d’intérêt (EOI) sur le site Web du défi : www.dreamschallenge.org avant le 28 mars 2016 à 23 h 59 heure avancée de l’Est (HAE). Les candidatures seront examinées et les finalistes seront invités à soumettre une candidature.

Pour obtenir davantage d’informations sur le défi ou pour présenter votre candidature, visitez le site Web du défi de l’innovation DREAMS, www.dreamschallenge.org. Les candidats intéressés peuvent télécharger l’annonce de possibilité du défi pour obtenir des informations détaillées concernant les exigences en matière de candidature, ainsi que les conditions.

À propos de Johnson & Johnson

Prendre soin de chacun, individuellement : voilà ce qui inspire et unit les salariés de Johnson & Johnson. Nous soutenons la recherche et la science en proposant des idées, produits et services innovants dans le but d’améliorer la santé et le bien-être de tous. Notre société, qui emploie quelque 128 000 personnes dans plus de 265 sociétés exploitantes Johnson & Johnson, collabore avec des partenaires dans le domaine de la santé. Nos activités profitent quotidiennement à plus d’un milliard de personnes à travers le monde.

Johnson & Johnson Issues Call for Innovative Ideas to Reduce HIV Infections in Sub-Saharan Africa

DREAMS Partners Announce $85 Million Innovation Challenge Focused on Solutions for Adolescent Girls and Young Women

NEW BRUNSWICK, New Jersey, Feb. 17, 2016 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today issued a call for innovative ideas as part of the DREAMS Innovation Challenge, which is supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), Janssen Pharmaceutica, NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and ViiV Healthcare. Proposals are currently being accepted for breakthrough innovations to reduce HIV infections in adolescent girls and young women in 10 sub-Saharan African countries. The submission deadline to be considered for an award is March 28, 2016.

Johnson & Johnson issued a call for innovative ideas to reduce HIV infections in adolescent girls and young women in sub-Saharan Africa as part of the DREAMS Innovation Challenge, sponsored by Janssen Pharmaceutica, NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), and ViiV Healthcare.

Photo – http://photos.prnewswire.com/prnh/20160216/333964

A total of $85 million will be awarded for innovative, sustainable solutions to six Challenge Focus Areas that will give young women the opportunity to live the Determined, Resilient, Empowered, AIDS-Free, Mentored, and Safe lives they deserve. Winning solutions must demonstrate readiness for rapid implementation in one or more of the 10 DREAMS countries and ability to show impact within two years with potential for long-lasting change.

“We believe that breakthrough innovations needed to reduce the HIV infections in adolescent girls and young women can come from anywhere in the world,” said Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. “Our hope in supporting the DREAMS Innovation Challenge is to unleash new ideas to help us achieve by the end of 2017, 40 percent reduction in HIV infections among adolescent girls and young women living in 10 sub-Saharan countries.”

AIDS is the leading cause of death among women of reproductive age in low- and middle-income countries. Adolescent girls and young women account for 380,000 new infections a year or more than 7,000 new infections a week globally.

“While we have made considerable progress in the global response to HIV/AIDS, adolescent girls and young women have been largely left behind,” said Ambassador Deborah L. Birx, U.S. Global AIDS Coordinator and U.S. Special Representative for Global Health Diplomacy. “With girls and young women accounting for 71 percent of all new HIV infections among adolescents in sub-Saharan Africa, we urgently need innovative solutions that empower them to protect their health and pursue their dreams.”

“New thinking and high-impact approaches are needed to address the many complexities that drive this urgent health crisis,” said Jaak Peeters, head of Johnson & Johnson’s Global Public Health organization. “By addressing the factors and complexities that impact these young women at a fundamental level, we hope to measurably improve health outcomes and create enduring change. These are important components of Johnson & Johnson’s approach to improving global public health.”

Johnson & Johnson, through its Janssen Pharmaceutical Companies, joined the DREAMS Partnership as an anchor partner last December. The ambitious $385 million partnership delivers a Core Package of evidence-informed approaches that go beyond the health sector, addressing the structural drivers that directly or indirectly increase girls’ HIV risk, including poverty, gender inequality, sexual violence, and lack of education. The DREAMS Partnership also includes PEPFAR, the Bill & Melinda Gates Foundation, Girl Effect, Gilead Sciences, and ViiV Healthcare.

Delivering Sustainable Impact in Global Public Health

Combatting HIV is an important component of Johnson & Johnson’s long-standing legacy of commitment and partnership to improve global public health for individuals, families and communities worldwide. Through its global public health organization, the company aims to deliver integrated evidence-based solutions to address comprehensive health needs and deliver meaningful and enduring impact in three core focus areas: HIV, maternal and child health, and extensively drug-resistant (XDR)- and Multidrug-resistant (MDR)- tuberculosis (TB).

DREAMS Innovation Challenge Application Information

The DREAMS Partnership expects to announce the winners in mid-July followed by implementation in early fall 2016. Challenge awards will range from $100,000 to $40 million. Solutions are sought for implementation in Kenya, Lesotho, Malawi, Mozambique, South Africa, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe.

Applicants must submit an Expression of Interest (EOI) on the Challenge website: www.dreamschallenge.org by March 28, 2016 at 11:59 PM Eastern Daylight Time (EDT). Submissions will be reviewed, and finalists will be invited to submit an Application.

For more information about the Challenge or to apply, visit the DREAMS Innovation Challenge website, www.dreamschallenge.org. Interested applicants may download the Challenge Opportunity Announcement for full details about application requirements and terms and conditions.

About Johnson & Johnson

Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen

– Company Has Produced More Than 400,000 Vaccine Regimens for Use in Large-Scale Clinical Trials by April 2015

NEW BRUNSWICK, New Jersey, Jan. 6, 2015 / PRNewswire – Johnson & Johnson (NYSE: JNJ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.

Johnson & Johnson also announced today that Janssen, in partnership with Bavarian Nordic A/S, has produced more than 400,000 regimens of the prime-boost vaccine for use in large-scale clinical trials by April 2015. A total of 2 million regimens will be available through the course of 2015, with the ability to quickly scale up to 5 million regimens, if required, over a 12- to 18-month period. This increased projection is an update to Janssen’s previous goal of producing more than 1 million regimens by the end of 2015, with 250,000 regimens for broad application in clinical trials by May 2015.

“As a leader in the field of global health, we have a responsibility to act swiftly as Ebola continues to cause suffering among patients, families and health care workers in West Africa,” said Alex Gorsky, Chairman and CEO of Johnson & Johnson.

Modelling by the London School of Hygiene and Tropical Medicine to advise the World Health Organization (WHO) indicates that to bring the epidemic under control, current projected demand for a preventive vaccine ranges from a minimum of 100,000 doses to protect frontline workers to a high-end of 12 million doses for large-scale adult vaccination in the three affected countries.

“Because every day counts, we are substantially accelerating the production of our vaccine regimen,” said Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. “Through the unprecedented collaboration among the global health community, our goal is to bring this vaccine to families and frontline health care professionals as fast as possible.”

The Phase 1, first-in-human study will evaluate the safety and tolerability of a prime-boost vaccine regimen, in which patients are first given a dose to prime the immune system, and then a boost intended to enhance the immune response over time. The immune response generated by the regimen will also be evaluated longer term. Different regimens combining the vaccine components or placebo will be studied in 72 healthy adult volunteers. Additional clinical studies are planned to begin in the United States later this month and soon after in Africa. Further details of the study are posted on clinicaltrials.gov.

“We’ve been working at an unprecedented pace together with our partners to significantly accelerate our efforts,” said Dr. Matthew Snape of the Oxford Vaccine Group and the study leader. ”Initiating this study in the space of eight weeks represents a critical leap forward in being able to rapidly develop an Ebola prime-boost vaccine regimen, and these results will be vital to the design of future studies in broader populations.”

In October 2014, Johnson & Johnson announced a commitment of up to $200 million to accelerate and significantly expand production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. The company is seeking to share the financial risk of these vaccine and development clinical trial costs by pursuing governmental and non-governmental funding sources. The vaccine regimen, which was discovered in a collaborative research program with the National Institutes of Health (NIH), uses a prime-boost combination of two components that are based on AdVac® technology from Crucell Holland B.V., one of the Janssen Pharmaceutical Companies, and the MVA-BN® technology from Bavarian Nordic, a biotechnology company based in Denmark.

The Crucell Holland B.V. program received direct funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, under Contract Numbers HHSN272200800056C, and HHSN272201000006I and HHSN272201200003I, respectively. Preclinical experiments of the prime-boost vaccine regimen conducted by the NIH demonstrated that when both vaccines were administered two months apart, complete protection from death due to Ebola was achieved against the Kikwit Zaire strain, which is similar to the virus that is the cause of the current outbreak in West Africa. The research collaboration for a monovalent vaccine targeting the Zaire strain of the Ebola virus is part of an ongoing development program for a multivalent vaccine against all virus strains that cause disease in humans, including Ebola and Marburg viruses based on the Ad26 and Ad35 vectors.

The Johnson & Johnson Family of Companies continues to closely collaborate with WHO, NIAID and the European Commission, as well as other key stakeholders, governments, public health authorities, and non-governmental organizations on the clinical testing, development, production and distribution of the vaccine.

The effects of Ebola in West Africa continue to significantly strain the health care systems of Liberia, Sierra Leone and Guinea. Johnson & Johnson disaster response efforts continue through its support of Direct Relief International, Partners in Health, AmeriCares, IntraHealth and Project HOPE. The company also supports the ongoing efforts by public health authorities, including the U.S. Centers for Disease Control and Prevention and WHO, to mount a coordinated world response to address the immediate needs raised by the Ebola outbreak. As part of its commitment to support nurses, Johnson & Johnson gave an educational grant to Nurse.com to make available to every nurse in the U.S. continuing education resources about Ebola.

About The Phase 1, First-in-Human Study of Heterologous Prime-Boost Ebola Vaccine Regimens

The volunteers in this study will be enrolled into four groups and randomized to receive either active vaccine or placebo. Those getting an active dose will receive a prime vaccination in one of four regimens according to randomization on day one and then receive the boost component either one or two months apart, depending on which group they are in. Analyses of these regimens will inform decisions for future studies, such as the order in which the two components should be given and how closely together they can be given to ensure the optimal protection and sustainability. Further details of the study are posted on clinicaltrials.gov.

About Johnson & Johnson
Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,000 employees at more than 270 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

About Crucell
Crucell Holland B.V. is part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and is focused on research, development and production of vaccines that prevent and/or treat infectious diseases. We have a broad development pipeline, with several product candidates based on our unique AdVac® and/or PER.C6® production technology.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.

Note on Forward Looking Statements

(This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995, including regarding product development and production. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product development, including the uncertainties of clinical success and the timeline for the availability of a potential vaccine against Ebola; the challenges and risks involved in large-scale production of a vaccine; and the uncertainty of the level of demand for a vaccine against Ebola. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)

Press Contacts:

Ernie Knewitz
+1 (732) 524-6623
+1 (917) 697-2318

Seema Kumar
+1 (908) 405-1144

Ronan Collins (EU)
+47 488 425 00

Investor Contacts:

Louise Mehrotra
+1 (732) 524-6491

Stan Panasewicz
+1 (732) 524-2524